CoChat

Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies

Open access
Young, Allan H, Calabrese, Joseph R, Gustafsson, Urban, Berk, Michael, McElroy, Susan L, Thase, Michael E, Suppes, Trisha, Earley, Willie · 2013 · International Journal of Bipolar Disorders

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite being present in up to 1% of the population, few controlled trials have examined the efficacy of treatments for bipolar II depression. Pooled data are presented from four placebo-controlled studies (BOLDER I [5077US/0049] and II [D1447C00135]; EMBOLDEN I [D1447C00001] and II [D1447C00134]) that evaluated the efficacy of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder. METHODS: All studies included an 8-week, double-blind treatment phase in which patients were randomly assigned to treatment with quetiapine 300 mg/day, quetiapine 600 mg/day, or placebo. Outcome measures included the change from baseline in MADRS total score at week 8, effect sizes, and MADRS response and remission rates. RESULTS AND DISCUSSION: Improvements in mean MADRS total scores from baseline to week 8 were significantly greater with quetiapine 300 and 600 mg/day (-15.58 [n = 283] and -14.88 [n = 289]; p < 0.001) compared with placebo (-11.61 [n = 204]). The MADRS effect sizes were 0.44 for quetiapine 300 mg/day and 0.47 for 600 mg/day (p < 0.001 vs placebo). Significantly higher proportions of patients receiving quetiapine, at both doses, than placebo-treated patients achieved response and remission at week 8 (p < 0.01). Common adverse events associated with quetiapine (both doses) included dry mouth, somnolence, sedation, dizziness, and headache. Rates of mania and hypomania were similar for quetiapine and placebo. Quetiapine monotherapy demonstrated significant efficacy compared with placebo and was generally well tolerated in the treatment of bipolar II depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2194-7511-1-10

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition.
Figure 1 Patient disposition.CC BY · PubMed Central
Figure 2 Mean change from baseline to week 8 in MADRS total score (ITT population; LOCF).
Figure 2 Mean change from baseline to week 8 in MADRS total score (ITT population; LOCF).CC BY · PubMed Central
Figure 3 Effect sizes of quetiapine 300 and 600 mg/day in patients with bipolar I or bipolar II disorder.
Figure 3 Effect sizes of quetiapine 300 and 600 mg/day in patients with bipolar I or bipolar II disorder.CC BY · PubMed Central
Figure 4 Relationship between MADRS total score at baseline and of treatment (ITT).
Figure 4 Relationship between MADRS total score at baseline and of treatment (ITT).CC BY · PubMed Central
Figure 5 Difference in mean change from baseline in MADRS individual item scores at week 8 (ITT population; LOCF).
Figure 5 Difference in mean change from baseline in MADRS individual item scores at week 8 (ITT population; LOCF).CC BY · PubMed Central
Figure 6 Mean change from baseline to week 8 in HAM-A total score (ITT population; LOCF).
Figure 6 Mean change from baseline to week 8 in HAM-A total score (ITT population; LOCF).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 2

  1. Angst J, Gamma A, Azorin JM, Bowden CL, Perugi G, Vieta E, Young AH: Evidence-based efforts to re-define bipolar disorders. Bipolar Disord 2011,13( Suppl 1):14.
  2. Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: treatment of bipolar disorder. Postgraduate Med Special Report 2004, 2004: 1–120.

Cited by

See all 38

Metadata

Authors
Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W.
Affiliations
  • King's College London (GB)
  • University Hospitals Cleveland Medical Center (US)
  • AstraZeneca (Sweden) (SE)
  • Mental Health Research Institute (AU)
  • Lindner Center of HOPE (US)
  • University of Pennsylvania (US)
  • VA Palo Alto Health Care System (US)
  • AstraZeneca (United States) (US)
Corresponding author
Young, Allan H
Venue
International Journal of Bipolar Disorders
Published
2013-07-04
Volume
1
Issue
1
Pages
10-10
ISSN
2194-7511 (ISSN-L)
OpenAlex
W2104877916
Cited by
35
References
61
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 3 · 2014: 6
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • International Journal of Bipolar Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
quetiapine, bipolar II depression, bipolar II disorder, monotherapy, atypical antipsychotics, antidepressant efficacy, remission, response rate, adverse events, dose comparison, Montgomery-Asberg Depression Rating Scale

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. https://app.cochat.ai/papers/10.1186/2194-7511-1-10
The paper
Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W. (2013). Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders. https://doi.org/10.1186/2194-7511-1-10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.